Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 26kWORD 20k
2 August 2019
P-002142/2019(ASW)
Answer given by Mr Avramopoulos on behalf of the European Commission
Question reference: P-002142/2019

The European Drug Report(1) published on 6 June 2019 by the European Monitoring Centre for Drugs and Drug Addiction gives a general overview of the European drug situation while the accompanying Country Drug Reports(2) give a detailed description of the national situations in each Member State.

These reports highlight the cross-border nature of the drug problem and the European Commission is convinced that — as set out in the EU Drug Strategy(3) and in the EU Action Plan on Drugs(4) — cooperation among Member States as well as at international level is the right way to counter the drug problem.

Initiatives of individual Member States aiming at combatting drug production and trafficking in the EU are coordinated within the EU Policy Cycle for organised and serious international crime for the period 2018 — 2021, which aims to tackle organised and serious international crime in a coherent and methodological manner(5). The Netherlands is active in this framework as well as it is participating in the actions taken under EU’s bold law enforcement response to drugs(6).

The European Commission has several financial instruments in place to support initiatives in the field of drugs(7) such as the Internal Security Fund — Police promoting law enforcement cooperation. It is up to the Netherlands to ensure that the national implementation programme appropriately funds a share of drug-related activities.

Regarding the Honourable Member’s last question, the European Commission recently launched an external evaluation of the 2013 — 2020 EU Drug Strategy and of the action plan 2017 — 2020.

(1)http://www.emcdda.europa.eu/edr2019_en
(2)The report concerning the Netherlands is available at http://www.emcdda.europa.eu/publications/country-drug-reports/2019/netherlands
(3)OJ C 402, 29.12.2012, p. 1‐10.
(4)OJ C 215, 5.7.2017, p. 21‐58.
(5)The EU Policy Cycle improves and strengthens cooperation between the relevant services of the Member States, EU institutions and EU agencies as well as third countries and organisations, including the private sector where relevant.
(6)https://www.europol.europa.eu/newsroom/news/drugs-in-europe-bold-law-enforcement-response
(7)Other instruments are for example the Justice Programme, the Health Programme, Horizon 2020.

Last updated: 5 August 2019Legal notice